tirzepatide surpass-4 trial: slows rate of eGFR decline and reduces UACR in T2DM patients New SURPASS-CVOT Ad Hoc Analysis:
Description
This is actually the most promising group for tirzepatide switching because the additional GIP stimulation can amplify the partial response you already have
doi: 10.1007/s12020-019-02155-w 75 EslamMNewsomePNSarinSKAnsteeQMTargherGRomero-GomezMet al
But once you escalate to 5 mg and beyond, the 30 mg vial becomes the clear winner in terms of value and convenience
But if the BUD is only 30 days, you can only use four doses before expiration, wasting roughly a third of the vial
However, some manufacturers might have different recommendations, as you mentioned, up to 90 days
Lancet Public Health
